Madrigal Pharmaceuticals Initiates Rolling Submission of New Drug Application for Resmetirom to FDA for NASH Treatment

Madrigal Pharmaceuticals, Inc. has announced the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of its drug resmetirom for the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. The company expects to complete the full submission of the NDA in July 2023. &nbsp Resmetirom was granted Breakthrough Therap..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 2.
  • textsms

Eccogene Raises CNY 180 Million in Series B Equity Financing for Treatments of Metabolic Diseases

Clinical-stage biotech company Eccogene has raised CNY180m ($25m) in series B equity financing to support the development of its clinical-stage pipeline. The funding round was led by New Alliance Capital and Zhangjiang Healthcare Venture Capital, and included new investors Rockbleu Capital, YuFu Investment, Huajin Capital and Elikon Venture, as well as existing backers Delos Capital, Oriza Seed ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 13.
  • textsms